Drug Trial Radar · NCT03927495
KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
May 22, 2019
Primary completion
Jun 30, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Shanghai Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Affiliated Hospital of Suzhou Medical College
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
KN046Drug
Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
palliative radiotherapyRadiation
3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
KN046Drug
Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- dose-limiting toxicity KN046Time frame: 28 days after first dose
- 6-month progression free survival rate assessed by investigator based on RECIST 1.1Time frame: 6 months after first dose
- Objective response rate assessed by investigator based on RECIST 1.1Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Suzhou University
Suzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.